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This work extends our previous observation that the fungus Candida albicans secretes micromolar levels of
farnesol and that accumulation of farnesol in vitro prevents the yeast-to-mycelium conversion in a quorum-
sensing manner. What does farnesol do in vivo? The purpose of this study was to determine the role of farnesol
during infection with a well-established mouse model of systemic candidiasis with C. albicans A72 administered
by tail vein injection. This question was addressed by altering both endogenous and exogenous farnesol. For
endogenous farnesol, we created a knockout mutation in DPP3, the gene encoding a phosphatase which
converts farnesyl pyrophosphate to farnesol. This mutant (KWN2) produced six times less farnesol and was ca.
4.2 times less pathogenic than its SN152 parent. The strain with DPP3 reconstituted (KWN4) regained both
its farnesol production levels and pathogenicity. These mutants (KWN1 to KWN4) retained their full dimor-
phic capability. With regard to exogenous farnesol, farnesol was administered either intraperitoneally (i.p.) or
orally in the drinking water. Mice receiving C. albicans intravenously and farnesol (20 mM) orally had
enhanced mortality (P < 0.03). Similarly, mice (n  40) injected with 1.0 ml of 20 mM farnesol i.p. had
enhanced mortality (P < 0.03), and the onset of mortality was 30 h sooner than for mice which received a
control injection without farnesol. The effect of i.p. farnesol was more pronounced (P < 0.04) when mice were
inoculated with a sublethal dose of C. albicans. These mice started to die 4 days earlier, and the percent survival
on day 6 postinoculation (p.i.) was five times lower than for mice receiving C. albicans with control i.p.
injections. In all experiments, mice administered farnesol alone or Tween 80 alone remained normal through-
out a 14-day observation period. Finally, beginning at 12 h p.i., higher numbers of C. albicans cells were
detected in kidneys from mice receiving i.p. farnesol than in those from mice receiving control i.p. injections.
Thus, reduced endogenous farnesol decreased virulence, while providing exogenous farnesol increased viru-
lence. Taken together, these data suggest that farnesol may play a role in disease pathogenesis, either directly
or indirectly, and thus may represent a newly identified virulence factor.
Candida albicans is a dimorphic commensal fungus which is
localized primarily in the gastrointestinal tract (20). It is a
medically important opportunistic pathogen, particularly for
immunocompromised individuals (16), and can invade a wide
range of organ systems during systemic infections. For healthy,
immunocompetent individuals, it is an opportunistic pathogen
only. However, Calderone and Gow (6), Navarro-Garcia et al.
(28), Naglik et al. (26), and Odds et al. (33) have detailed the
contributions of virulence factors in candidiasis. These viru-
lence factors could either promote Candida invasion or affect
host defense mechanisms. It is likely that the virulence of C.
albicans is multifactorial. Therefore, pathogenesis is the sum of
the attributes of the fungus, environmental conditions, and the
effectiveness of host defenses (6, 26, 28, 33). Virulence factors
which have been recognized so far include the following: (i)
morphogenesis—yeast-to-hypha switching is associated with
pathogenesis (5), presumably because it enables tissue invasion
(32) and evasion of host defense mechanisms (21); also, mu-
tants which can be regulated in vivo in their ability to undergo
the yeast-to-hypha transition were avirulent under conditions
that inhibited this transition (43); (ii) phenotypic switching
(47)—vaginal candidiasis is increased by high-frequency
switching between white and opaque colony morphologies
(48); (iii) epithelial adhesion—King et al. (17) first demon-
strated that C. albicans cells have greater adherence than do
cells of other Candida species, and their ability to interact with
mucosal epithelia correlates with their relative virulence (6);
and (iv) production of extracellular enzymes, both membrane-
damaging phospholipase B (1, 22) and the secretory aspartyl
proteases. Secretory aspartyl proteases are expressed during
human disease and are thought to be important virulence de-
terminants (8, 26, 39).
Recently Hornby et al. (12) identified farnesol as an extra-
cellular quorum-sensing molecule produced by C. albicans, and
these findings were independently confirmed by others (35,
36). Farnesol prevented mycelial development under growing
conditions (12) and in a differentiation assay using three chem-
ically distinct triggers for germ tube formation: L-proline, N-
acetylglucosamine, or serum (12). For all in vitro assays, far-
nesol prevented the yeast-to-mycelium conversion, resulting in
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actively budding yeasts without influencing cellular growth
rates (12). Recognizing that free farnesol is not normally de-
tected in human plasma (41), Hornby et al. (12) proposed two
competing hypotheses regarding the role of farnesol in disease
pathogenesis. The first hypothesis suggested that the shift from
yeasts to mycelia might be a critical step in pathogenesis and
that exogenous farnesol could block this transition, thus acting
as a therapeutic compound. An alternate hypothesis suggested
that the farnesol excreted during infection would alter the
membrane fluidity of host cells, allowing C. albicans to pene-
trate host tissues and thus indirectly acting as a virulence fac-
tor. The latter model is based on the lipophilic properties of
free farnesol, which would favor membrane localization.
The idea that farnesol might promote virulence is supported
by a recent study from our laboratory (27) on the pathogenicity
of C. albicans cells pretreated with subinhibitory concentra-
tions (0.5 to 1 M) of fluconazole. Previous studies (14) indi-
cated that these cells secreted 10 times more farnesol than did
untreated cells. Significantly, these fluconazole-pretreated cells
were also 4.2 to 8.5 times more lethal (P  0.001) than un-
treated cells in a mouse tail vein injection model of dissemi-
nated candidiasis (27). One explanation, but certainly not the
only explanation, for this enhanced pathogenicity is that it is
caused in some unknown fashion by the excess farnesol ex-
creted by the treated cells (14, 27).
The purpose of the present study was to determine whether
farnesol affected the progression of disseminated candidiasis
with a well-established mouse model and, if it did so, whether
it would act in a therapeutic or virulence-promoting manner.
We analyzed the effect of farnesol administered by different
routes, both endogenous and exogenous, and concluded that
farnesol excretion contributes to the virulence of C. albicans.
This is the first time that a fungal quorum-sensing molecule has
been suggested to play a role in C. albicans infection. It is also
the first investigation of DPP3 gene function in C. albicans,
showing its role in farnesol production.
MATERIALS AND METHODS
C. albicans strain and growth conditions. Candida albicans strain A72 (ATCC
MYA-2430) is a well-characterized farnesol-producing and farnesol-responsive
strain that has been used in previous in vitro studies (12, 13, 27, 45). This strain
was originally isolated from a patient by Antonio Cassone (Rome, Italy). C.
albicans strains 10231 and SN152 were obtained from the American Type Cul-
ture Collection (Rockville, MD) and Alexander Johnson, respectively. For chal-
lenge, C. albicans cells were grown for 24 to 30 h in 50 ml of mGSB medium at
30°C with aeration as previously described (12). For strains with auxotrophic
requirements, mGSB was supplemented with the required amino acid at 40
g/ml, i.e., Arg for KWN2, Arg and Leu for KWN1, Arg and His for KWN3, and
Arg, Leu, and His for SN152 and KWN4. Cells were harvested by centrifugation
at 4,750  g for 10 min and washed three times with 50 ml of sterile, nonpyro-
genic normal saline, before adjusting to the proper concentration in nonpyro-
genic sterile saline (Abbott Laboratories, North Chicago) using a Petroff-
Hausser counter. All strains were tested in vitro, i.e., stimulation by
N-acetylglucosamine at 37°C (12), to be sure that their germ tube-forming ability
was 95%. Samples were stored at 4°C overnight prior to injection. For strain
A72, the 50% lethal doses (LD50s) were found to be identical for cells stored
overnight and cells which were used immediately. Farnesol concentrations in the
culture supernatants were determined by gas chromatography/mass spectrometry
as described previously (12–14).
Mice and their inoculation with C. albicans. Mouse infections followed the
procedures recommended by Odds et al. (34). Outbred, 4- to 6-week-old (20 to
25 g), CF-1 female mice obtained from a commercial supplier (Charles River
Laboratories, Wilmington, MA) were randomly allocated to groups of five to six
animals and placed in polycarbonate cages with stainless-steel wire tops, using
aspen shavings as bedding material (laboratory-grade Sano-Chips; Harlan Tek-
lad, Madison, WI), and maintained on a 12-h light/dark cycle in heated, ther-
mostatically controlled rooms for the duration of the studies. The mice were fed
a commercial rodent diet (4% Mouse/Rat Diet 7001; Harlan Teklad, Madison,
WI) ad libitum. Tap water was provided in glass bottles fitted with stainless-steel
nipples mounted in rubber corks. After a 7- to 10-day observation period, each
group of mice was inoculated intravenously in the lateral caudal tail vein using a
27-gauge needle with 0.1 ml containing the appropriate concentration of C.
albicans cells. The degree of clinical illness in each mouse was evaluated three
times daily. In each experiment, mice that had severe clinical signs of illness were
euthanized immediately by placing them in a closed chamber filled with CO2 gas
and processed for complete necropsy and collection of tissues for histopatho-
logical, microbiological, and toxicological examinations. At the conclusion of the
experiment, all remaining mice were similarly euthanized for complete necropsy.
The experimental protocol, housing, and care of the mice were in accordance
with approved guidelines of the University of Nebraska—Lincoln Institutional
Animal Care and Use Committee.
Farnesol administration. Commercial mixed isomers or E,E-farnesol (Sigma,
St. Louis, MO) was diluted in 0.5% (vol/vol) of Tween 80 (Sigma) in sterile,
nonpyrogenic saline. The mixed isomers were used when farnesol was adminis-
tered orally. All other experiments used E,E-farnesol. The solubility of farnesol
in water is only 1.2 mM (18), and therefore, Tween 80 was used to increase the
concentration of farnesol which could be used. Farnesol (20 mM) was adminis-
tered either orally in the drinking water (without saline) or by intraperitoneal
(i.p.) injections. Mice received 1.0 ml of 20 mM farnesol (4.4 mg) by intraperi-
toneal (i.p.) injection. Water intake was monitored daily by the weight of the
water bottles for both the control and treated mice.
DPP3 knockout. To knock out the DPP3 gene, we adapted the strategy re-
ported by Noble and Johnson (31) using strain SN152, which is auxotrophic for
arginine, leucine, and histidine. This strategy is shown in Fig. 1. See Table 1 for
the sequences of all PCR primers. The sequences of both copies of DPP3 and
their respective flanking regions are identical in the diploid C. albicans genome
(Candida DB and CGD databases). The first step of the scheme involved am-
plification of the two 350-bp flanking regions of DPP3 using a template of
SC5314 genomic DNA and primers 1 and 3 or 4 and 6 (Fig. 1) in separate
reactions. These primers are designated DPP1, -3, -4, and -6, respectively, in
Table 1.
Plasmids pSN40 (containing Candida maltosa LEU2) and pSN52 (containing
Candida dubliniensis HIS1), kindly provided by Alexander Johnson, were trans-
formed into Escherichia coli cells, and following growth, the plasmids were
harvested. Universal primers 2 and 5 were used to amplify the HIS1 and LEU2
cassettes from these plasmids (31). The 5 tails of primers 2 and 3 and primers
4 and 5 are complementary, as is required for the fusion reaction. The upstream
and downstream 350-bp sequences for DPP3 and the respective selectable mark-
ers (His1 or Leu2) were combined, and the fusion products were amplified with
primers 1 and 6 (Fig. 1B).
PCR conditions to make the DNA fragments required for the DPP3 gene
disruption were as follows. In the first round of PCRs, 50-l reaction mixtures
combined 1 l of Klen Tac LA DNA polymerase (BD Bioscience) in 1 Klen
Tac buffer with 3 l of 10 mM deoxynucleoside triphosphate, 1 l of each primer
(100 ng/l), and 1 l of template DNA. The template for the flanking sequences
was SC5314 genomic DNA, and the templates for the C. maltosa LEU2 and C.
dubliniensis HIS1 markers were pSN40 and pSN52, respectively. The reaction
conditions were 93°C for 5 min and then 35 cycles of 93°C for 30 s, 45°C for 45 s,
and 72°C for 3 min, followed by a final 72°C for 10 min. All products were gel
purified on a 1% agarose gel, and the QIAquick gel extraction kit (QIAGEN)
was used to obtain ultrapurified DNA fragments. The PCR conditions for the
fusion reactions were identical to the above method except that the PCR elon-
gation reaction was extended to 72°C for 4.5 min. Template DNA consisted of 1
l of the upstream and downstream fragments and a marker DNA fragment (C.
maltosa LEU2 or C. dubliniensis HIS1). Because of the complementary overhangs
created in the initial DNA products, the fragments and markers anneal together.
Primers 1 and 6 amplified the fusion reactions (Fig. 1B), whereupon the fusion
PCR products were gel purified using the QIAquic gel extraction kit (QIAGEN).
The HIS1-containing fusion product was transformed into SN152 using the
lithium acetate method (Fig. 1A). Transformants were plated on selective me-
dium (yeast nitrogen base without amino acids but with arginine and leucine)
where only transformed cells will grow. KWN1 was selected.
Genomic DNA from the single-copy-deleted mutant (KWN1) was harvested
and checked for the correct insertion into one copy of DPP3 (Fig. 2, lanes B and
C). After confirming the single-copy knockout, the fusion product with the C.
maltosa LEU2 marker was transformed into KWN1 to knock out the other allele
of DPP3. Transformants were plated on selective medium (yeast nitrogen base
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without amino acids but with arginine) where only transformed cells will grow.
KWN2 was selected.
To confirm that the HIS1 and LEU2 cassettes had been inserted correctly, the
following primer pairs were used to span the junction sites (Table 1 and Fig. 1C):
HIS1 Left (near primer 2) and DPP3 upstream check for the HIS1 5 junction;
HIS1 Right (near primer 5) and DPP3 downstream check for the HIS1 3
junction; LEU2 Left (near primer 2) and DPP3 upstream check for the LEU2 5
junction; and LEU2 Right (near primer 5) and DPP3 downstream check for the
3 LEU2 junction. Confirmation of correct insertion in DPP3 was provided by
detecting PCR products of the expected size (Fig. 2). As a final check to confirm
the absence of DPP3 or a similar gene, possibly due to gene duplication in the
evolutionary process, the DPP3 check left and right primers (Table 1) were used
to amplify an 856-internal-base-pair region of the 921-bp sequence of DPP3.
Genomic DNA from KWN2 was used as the test sample and genomic DNA from
SN152 as the positive control. A southern hybridization confirmed the complete
absence of DPP3 (Fig. 3).
FIG. 1. Strategy used to disrupt and then reconstitute C. albicans DPP3. It merges the fusion PCR and heterologous marker protocols of Noble
and Johnson (31) with the SAT1 flipper protocols of Reu et al. (37). (A) Schematic diagram showing the method used to disrupt both alleles of
DPP3. (B) Construction of disruption fragments for homologous recombination. Primers 1 and 3 and primers 4 and 6 were used to amplify the
350-bp flanking sequences upstream and downstream of DPP3, respectively. Primers 2 and 5 were used to amplify the two selectable markers. Red
and green tails of primers are complementary sequences (31) needed for mutual primed synthesis in the fusion reaction. (C) 5 and 3 junctions
of the selectable marker integration sites were confirmed using the primers mentioned. (D) Structure of the deletion cassette from pSFS2ADPP3
(top) in which the SAT1 flipper is inserted between two downstream fragments of DPP3. The genomic structure of KWN2 (middle) shows that the
DPP3 allele has been replaced by one of the auxotrophic markers His1 and Leu2 (cross-hatched). Complementation of the DPP3 allele replacing
the His1 marker (after flip-mediated excision of the nourseothricin marker) was used to create KWN3 (lower). dwstream, downstream.
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DPP3 complementation method. (i) Plasmid construction. The pSFS2A plas-
mid was kindly provided by Joachim Morschhauser of the University of Wiirz-
burg, Germany. This plasmid has a gene deletion or complementation cassette,
called the SAT1 flipper cassette, which contains the nourseothricin marker
caSAT1 and the C. albicans-adapted FLP gene (caFLP), which encodes a site-
specific recombinase under the control of the C. albicans MAL2 promoter. The
cassette is flanked by direct repeats of the minimal recombination target sites of
the FLP recombinase. The SAT1 flipper cassette has been designed to contain a
few unique restriction sites on the left (ApaI and XhoI) and right (SacI and
SacII) borders that can be used to clone target sequences for homologous
recombination (37). The DPP3 complementation cassette was constructed as
follows. An ApaI-XhoI fragment of the complete C. albicans DPP3 sequence as
FIG. 2. Confirmation of the correct integration sites for the select-
able markers used to knock out DPP3. His1dpp upstream check, the
HIS1 Left and DPP3 upstream check primers were used to amplify
the upstream region of the construct; His1dpp downstream check, the
HIS1 Right and DPP3 downstream check primers were used to amplify
the downstream region of the construct; Leu2dpp upstream check, the
LEU2 Left and DPP3 upstream check primers were used to amplify
the upstream region of the construct; Leu2dpp downstream check, the
LEU2 Right and DPP3 downstream check primers were used to am-
plify the downstream region of the construct.
FIG. 3. Southern analysis of ClaI-digested genomic DNA of
SN152, KWN2, and KWN4 with two DPP3-specific probes. The two
probes hybridize with the bp 350 and 456 regions of the gene,
which has a single restriction site for ClaI at nucleotide 514. The sizes
of the hybridizing fragments (in kb) are given on the left side of the
blot. Fragments corresponding to hybridization at 3.7 kb are identical
in size for the parent strain (SN152) and the complemented strain
(KWN4). The KWN4 fragment corresponding to the other probe,
hybridizing at 5 kb, is slightly different from that of the parent strain.
TABLE 1. Sequences of synthetic oligonucleotides used in this study
Sequencea Name Reference
GTTCCATCAAATTATTCATTC DPP1 This study
ccgctgctaggcgcgccgtgACCAGTGTGATGGATATCTGC Universal primer 2 (for HIS1, LEU2, and ARG4 cassettes) 31
cacggcgcgcctagcagcggGATGAAAATGTGTAGAGTGTG DPP3 This study
gtcagcggccgcatccctgcTCAATAGGTTACTACTTAGC DPP4 This study
gcagggatgcggccgctgacAGCTCGGATCCACTAGTAACG Universal primer 5 (for HIS1, LEU2, and ARG4 cassettes) 31
AGCAGGTCAAGATGCAATG DPP6 This study
ATTAGATACGTTGGTGGTTC HIS1 Left (near primer 2) 31
AACACAACTGCACAATCTGG HIS1 Right (near primer 5) 31
AGAATTCCCAACTTTGTCTG LEU2 Left (near primer 2) 31
AAACTTTGAACCCGGCTGCG LEU2 Right (near primer 5) 31
TGGGATAAGCCTCATACATGC DPP3 Upstream Check This study
CAAAGGGAACAAGATGAAGCA DPP3 Downstream Check This study
GGGGGTTTAAATCACCAACA DPP3 Check Left This study
CACACATTAGTGGAAATGTC DPP3 Check Right This study
GGATAAGGGCCCTCATACATGCAA DPP3 complement 1 This study
TCAAGCTCGAGGTAATTCAGAAAAGAA DPP3 complement 2 This study
CCCACCGCGGCTAGTCTTGGTCTA DPP3 complement 3 This study
CCATAGAGCTCATTCTTTCAAGTGGGTA DPP3 complement 4 This study
a Sequences in lower case correspond to exogenous, complementary sequences introduced for mutually primed synthesis in the second round of fusion PCR.
Underlined segments introduce desired restriction sites in the process of constructing pSFS2ADPP3.
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well as 0.5 kb of upstream and 0.46 kb of downstream flanking sequences for the
DPP3 alleles were amplified using primers DPP3 complement 1 and 2 (Table 1).
A SacII-SacI DPP3 downstream fragment from position 20 to 476 was am-
plified with primers DPP3 complement 3 and 4 (Table 1). DPP3 together with up-
and downstream fragments was cloned on the left side of the SAT1 flipper and
the DPP3 downstream fragment was cloned on the right side of the SAT1 flipper
(Fig. 1D) to generate pSFS2ADPP3. The SAT1 flipper cassette and the cloned
parts of the plasmids were sequenced at the University of Nebraska, Lincoln,
sequencing facility to confirm accurate cloning.
(ii) C. albicans transformation to reconstitute DPP3. Transformation for
complementation was done according to the method of Reu et al. (37). Briefly,
the insert from pSFS2ADPP3 was excised as an ApaI-SacI fragment and gel
purified. Approximately 1 g (5 l) of the linear DNA fragment was mixed with
40 l of electrocompetent KWN2 cells and subjected to electroporation (0.2-cm
cuvette; 1.8 kV). These electroporated KWN2 cells were washed with 1 ml of 1
M sorbitol, resuspended in 1 ml of yeast extract-peptone-dextrose (YPD), and
incubated for 4 h at 30°C with shaking at 200 rpm. The cells were spread on YPD
plates containing 200 g/ml nourseothricin and inoculated at 30°C. Resistant
colonies were picked after 1 day and reinoculated into YPD liquid medium with
200 g/ml nourseothricin. Eight cultures from individual colonies were streaked
on synthetic dextrose agar (SD)-plus-Arg, SD-plus-Arg-and-His, and SD-plus-
Arg-and-Leu plates to determine which copy of DPP3 had been reintegrated.
After confirming that one of the markers introduced into SN152 had been lost,
that strain was named KWN3. KWN3 was inoculated into YPD liquid medium
without selective pressure to allow FLP-mediated excision of the SAT1 flipper
cassette as described by Reu et al. (37). Then, serially diluted KWN3 was
spread on YPD plates containing 25 g/ml nourseothricin and allowed to grow
for 2 days to identify those smaller colonies that are nourseothricin sensitive due
to FLP-mediated excision of CaSAT1. These colonies were reinoculated into
yeast peptone maltose liquid medium to make sure that the MAL2 promoter was
activated for caFLP expression. This precaution was taken in case there were any
nonexcised CaSAT1 cassettes remaining. These cells were restreaked on YPD
containing 200 g/ml nourseothricin (where they should not grow) to make sure
that FLP-mediated excision had occurred and then transformed again with the
same ApaI-SacI fragment to make KWN4, with fully reconstituted DPP3.
Nourseothricin was obtained from Werner BioAgents (Jena, Germany).
Southern hybridization. Genomic DNA from SN152, KWN2, and KWN4 was
isolated for Southern hybridization. Both alleles of DPP3 have ClaI restriction
cut sites at nucleotide 514. Approximately 10 g of DNA was digested with ClaI,
separated on 1% agarose gels, and transferred to a membrane. Two gel-purified
DPP3 fragments were used as probes to confirm gene knockout and comple-
mentation. These were the upstream fragment (350 bp) generated by primers
DPP1 and DPP3 and the SacII-SacI downstream fragment (456 bp) generated by
primers DPP3 complement 3 and complement 4.
Determination of C. albicans LD50s. The LD50s for C. albicans A72, SN152,
KWN2, and 10231 were determined by the Kärber method (23). Strains of C.
albicans were inoculated into mGSB medium, grown overnight at 30°C, washed
three times with nonpyrogenic, sterile saline, and counted with a Petroff-Hausser
counter. Five groups of five mice each were intravenously (i.v.) challenged by tail
vein injection with 0.1 ml of sterile saline containing either 104, 105, 106, 107, or
108 yeast cells. Mortality was recorded continuously for 7 to 14 days postinocu-
lation (p.i.), and the LD50 was calculated by the Kärber method (23). For C.
albicans A72, the calculated LD50 was approximately 1.3  106 cells at 3 days p.i.
This protocol was modified slightly to achieve a sublethal challenge. C. albicans
A72 was transferred in mGSB nine times over a 9-month period. These cells still
had germ tube-forming ability of 95%, but their LD50 at 3 days p.i. had
increased to 1.0  107 cells. In this case, 1.3  106 cells was a sublethal injection.
For the pathogenicity experiment comparing strains SN152, KWN2, and
KWN4 (50 mice total), each group of 15 mice was inoculated with 2  106
cells of the indicated strain. Five mice were kept as a negative control. The
injection dose of 2  106 cells was chosen to coincide with the 3-day LD50 of
SN152 (Table 2).
Statistical analysis. The main parameter measured was the time (h) from i.v.
inoculation to death or euthanasia because of severe clinical signs. The data were
plotted as Kaplan-Meier survival curves and analyzed using LIFETEST and
proportional hazards regression (PHREG) procedures (42). The LIFETEST
assesses model assumptions using three nonparametric tests, log-rank, Wilcoxon,
and likelihood ratio tests, to determine whether two or more treatment groups
are different. PHREG performs Cox regression analysis of survival data using the
proportional hazards model. The resulting regression coefficients are an estimate
of the exponent of the hazard ratios or relative risk.
Fluorescent farnesol in sera. In order to determine how much farnesol gets to
the bloodstream and how long it remains there, we developed a high-perfor-
mance liquid chromatography (HPLC) method to detect fluorescent farnesol in
mouse serum. Shchepin et al. (44) designed a farnesol analog which exhibits
absorption and emission near 360 and 450 nm, respectively. This molecule is
biologically active in that it has 12% of the activity of farnesol in blocking the
yeast-to-mycelium transition by C. albicans (44). However, the fluorescent far-
nesol was only partially soluble in 0.5% Tween 80. For this preliminary experi-
ment, we suspended 130 mg of fluorescent farnesol in 30 ml of 0.5% Tween 80
(equivalent to 20 mM) and injected 1 ml per mouse of the solubilized portion i.p.
into 27 mice. At time points of 10 min and 1, 3, 6, 12, 18, 24, 48, and 72 h p.i.,
three mice were euthanized and their serum (200 l) collected. Serum of four
untreated mice was collected as a negative control.
For each time point, the serum samples were pooled, extracted with ethyl
acetate, and fractionated on an HPLC system (ISCO, Lincoln, NE) with a C18
reverse-phase column (Vydac) and a fluorescence detector (ISCO) set at an
excitation of 360 nm and an emission of 450 nm. We detected twin peaks for
fluorescent farnesol at ca. 13.3 and 15.3 min of retention time using acetonitrile
and water for the mobile phase. The mobile-phase gradient went from 30 to 50%
acetonitrile (1 to 5 min), 50% acetonitrile (5 to 15 min), 50 to 100% acetonitrile
(15 to 20 min), and 100 to 30% acetonitrile (20 to 25 min). A standard curve was
constructed with fluorescent farnesol added to normal mouse serum at concen-
trations of 2.3 to 230 M; more than 98% was detected by HPLC.
C. albicans isolation and quantitative determination. Three mice from each
group were euthanized at 1, 3, 6, 12, 18, 24, or 48 h to determine the fungal
burden in their kidneys. At the time of necropsy, kidneys were harvested from
each mouse and placed in sterile Eppendorf tubes. The tissues were kept at 4°C
until the next day, when each kidney was weighed and homogenized in 2.0 ml of
nonpyrogenic sterile saline. Then, 0.1 ml of the homogenate was spread on
triplicate plates of Nickerson’s medium, also known as BiGGY agar, a selective
and differential medium for C. albicans (30). After 48 h of incubation at 30°C,
colony number, morphology, and color were recorded and numbers of CFU per
gram of tissue was estimated. C. albicans appears as brown to black colonies with
no pigment diffusion and no sheen (30).
RESULTS
Reduced endogenous farnesol reduces virulence in mice. We
disrupted the first DPP3 locus with C. dubliniensis HIS1 (Fig.
1A) and then confirmed that it had been inserted correctly by
the presence of the expected upstream (Fig. 2, lane B) and
downstream (Fig. 2, lane C) HIS1/DPP3 junction sequences.
This heterozygous mutant was named KWN1, and it was used
to disrupt the other allele of DPP3 with C. maltosa LEU2. This
double-knockout mutant was named KWN2. We confirmed
that the LEU2 marker had been inserted correctly by the
presence of the expected upstream (Fig. 2, lane D) and down-
stream (Fig. 2, lane E) LEU2/DPP3 junction sequences. Fi-
nally, the overall success of the DPP3 gene knockout was
confirmed by its presence in SN152 and its absence in KWN2
TABLE 2. Altered pathogenicity by strains of C. albicans altered in
their levels of farnesol production
Strain
Amt of farnesol
produced
(g/g dry wt	)
LD50a
3 days p.i. 7 days p.i. 14 days p.i.
SN152 10.9 
 1.7 1.9  106 7.9  105 5  104
KWN1 1.65 
 0.5 — — —
KWN2 1.79 
 1 7.9  106 1.9  106 5  105
KWN3 11.5 
 4.4 — — —
KWN4 21.2 
 1.2 2  106 — —
ATCC 10231 Undetectedb 1.2  107 — —
a LD50 for KWN4 was obtained from Fig. 4. All other LD50s were calculated
(see Materials and Methods) from experiments where mice were inoculated with
five different cell densities (104 to 108 cells/ml). Note that the other two LD50s
obtained from Fig. 4 (2  106 for both SN152 after 3 days and KWN2 after 7
days) agree very well with the values from the five inoculum-level experiments.
—, not done.
b See reference 14.
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as determined by both PCR (data not shown) and Southern
hybridization (Fig. 3). Survival curves for the two strains were
then compared with that for immunocompetent mice. The
calculated LD50s for strains SN152 and KWN2 are presented
in Table 2. Comparison of the SN152 parent with the DPP3
double-knockout mutant shows that the mutant produced ca.
six times less farnesol and was 4, 2.4, and 10 times less patho-
genic to mice at 3, 7, and 14 days, respectively (Table 2).
Pathogenicity was restored when DPP3 was reconstituted
(Fig. 4). The first reconstituted strain (KWN3) regained a
single copy of DPP3 while losing the His marker. The HIS
marker was the first to be integrated in place of one of the
DPP3 alleles (creating KWN1) and the first to be replaced
(creating KWN3). Next, KWN3 was transformed, regaining a
second copy of DPP3 while losing the Leu marker. KWN4, like
SN152, is auxotrophic for Arg, His, and Leu. The accuracy of
these genetic manipulations was confirmed by two methods:
PCR amplification of the His or Leu junctions and Southern
hybridization. Southern hybridization (Fig. 3) confirmed the
absence of DPP3 in KWN2 and the reintegration of DPP3 in
KWN4. For SN152, probes for the up- and downstream re-
gions of DPP3 (Fig. 1D) hybridized in the southern blot at
approximately 6.0 kb and 3.7 kb. The same probes for KWN2
hybridized to fragments at approximately 2 kb and 7 kb, re-
spectively (Fig. 3). SN152 and the complemented strain
(KWN4) had one hybridization band of the same size at 3.7 kb
(Fig. 3), but the probe corresponding to the 6-kb fragment in
SN152 hybridized with a fragment of approximately 5.0 kb in
the reconstituted strain KWN4. One reason that the hybrid-
ization bands are of different sizes for SN152 and KWN4 (Fig.
3) is that during complementation the SAT1 flipping technique
(37) causes the 460-bp downstream fragment to be duplicated.
However, any doubt regarding the correct integration of DPP3
is removed by the disappearance of the auxotrophic markers
which disrupted the gene originally (Fig. 1).
For the reconstituted strains, the farnesol production level
was restored to parental levels in KWN3 and doubled in
KWN4 (Table 2). With regard to mouse pathogenicity (Fig. 4),
the SN152 and KWN4 survival curves were not different from
each other (P  0.96), but they were both significantly different
(P  0.0014 or 0.0017, respectively) from the KWN2 group.
The PHREG hazard ratio estimates indicated that SN152 and
KWN4 cells had 4.1 and 4.2 times higher lethality than KWN2
cells, respectively.
Mutants altered in farnesol production have unaltered cell
and colony morphology. The four strains altered in their far-
nesol production levels, KWN1 to -4, appeared normal in their
dimorphic abilities. That is, at 30°C they grew as yeasts in both
YPD and mGSB media (12) and at 37°C they formed 95%
germ tubes in 2.5 mM N-acetylglucosamine buffer (12) and
filamentous colonies on spider medium (24). No further tests
on cell morphology were conducted.
Additionally, C. albicans ATCC 10231, a natural strain
which produces farnesoic acid (35) but not farnesol (14), also
exhibited normal cell and colony morphology. However, it did
exhibit reduced pathogenicity. The LD50 dose for strain 10231
after 3 days was 1.2  107 cells (Table 2). The reduced viru-
lence of 10231 compared to those of other wild-type strains was
also observed by Kretschmar et al. (19).
Nontoxicity of exogenous farnesol. The safety of farnesol
administered orally in the drinking water (20 mM without
saline) and intraperitoneally (1 ml of 20 mM) was evaluated.
Because farnesol was diluted in Tween 80, the effect of i.p.
administration of Tween 80 alone was also evaluated. Farnesol
and Tween 80 had a negligible toxic effect on the mice. In each
experiment, the weight of individual mice and the consumption
of water in control and treated groups were recorded daily for
14 days. Irrespective of the route of administration and the
concentration of farnesol and Tween 80, there was no diarrhea
or mortality. Furthermore, there were no significant differ-
ences in either weight gain or water consumption between the
control and treated groups throughout the 14-day observation
period. Additionally, significant gross changes were not seen in
control and treated mice examined at necropsy on day 14 p.i.
These results are consistent with those of a previous study (2),
which found that the LD50 of i.p. farnesol for mice was 2.95
g/kg of body weight, which corresponds to 75 mg for a 25-g
mouse. For comparison, 1 ml of 20 mM farnesol contains only
4.4 mg of farnesol.
Exogenous oral farnesol increases mouse mortality. The
effect of farnesol by oral delivery was investigated (Fig. 5).
Seven mice per group were challenged with an LD50 dose of C.
albicans. The first group received C. albicans and regular drink-
ing water, while the second group received farnesol orally (20
mM farnesol–Tween 80 in the drinking water). Figure 5 dem-
onstrates enhanced mortality (P  0.036) for the group receiv-
ing oral farnesol. Thus, exogenous farnesol acts to enhance the
virulence of C. albicans.
Exogenous i.p. farnesol increases mouse mortality. Farnesol
given i.p. affected both the onset of mouse mortality and the
percent survival (Fig. 6). Forty mice per group were inocu-
lated i.v. with 1.3  106 C. albicans cells, with a 1.0-ml i.p.
injection of either 20 mM farnesol or 0.5% Tween 80–saline
(vol/vol). Farnesol enhanced the lethality of the systemic
Candida infection; the onset of mortality was 30 h sooner for
mice injected with farnesol (Fig. 6). In all cases the kidneys
showed the same histopathology regardless of the route
(oral versus i.p.) of farnesol delivery. The data were ana-
lyzed according to the log-rank, Wilcoxon, and likelihood
FIG. 4. Altered pathogenicity for C. albicans strains with DPP3
removed and restored. Fifteen mice per group, each injected with 2 
106 cells. E, SN152 parent; Œ, KWN2; F, KWN4.
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ratio tests. All three tests revealed that the survival curves
with and without i.p. farnesol differed from each other (P 
0.031). In all mouse experiments (Fig. 4 to 7), the farnesol-
only, Tween 80-only, and no-treatment control groups (five
mice per group) showed no mortality and had similar pat-
terns of weight gain.
A second experiment (Fig. 7) used 15 mice per group with a
sublethal C. albicans challenge. Both groups were challenged
with C. albicans and a 1-ml i.p. injection of either farnesol or
0.5% Tween 80–saline (vol/vol). Mice administered farnesol
i.p. started to die 4 days earlier, and by day 6 p.i. the percent
survival was five times lower than that for the no-farnesol
control mice (Fig. 7). The effect of i.p. farnesol administration
on percent survival was significant (P  0.048). From this
experiment we conclude that farnesol alone is responsible for
the enhanced C. albicans pathogenesis.
Time course of fluorescent farnesol in serum. A fluorescent
analog of farnesol with five conjugated double bonds (44) was
used to determine how much i.p. farnesol gets into the blood-
stream and how long it remains there. Serum samples were
analyzed by HPLC. The fluorescent farnesol was detected 10
min following i.p. injection. The levels reached a maximum (ca.
1 M) after 1 h, were barely detectable at 6 h, and had com-
pletely disappeared by 12 h. This rapid appearance and disap-
pearance of the fluorescent farnesol is likely relevant for dis-
ease progression, particularly in the early stages following i.p.
injection of farnesol (Fig. 6). Robert et al. (38), using very
similar experimental conditions, found that 98% of the in-
jected C. albicans cells had been cleared from the bloodstream
within 3 min and they were almost all gone within 15 min. For
Fig. 6 and 7, the farnesol i.p. injections occurred ca. 5 min after
the tail vein injections of C. albicans.
Exogenous i.p. farnesol speeds up kidney colonization. We
examined kidney colonization over time for 48 h p.i. (Fig. 8).
Two groups of 24 mice were administered C. albicans i.v.
accompanied by 1.0 ml of either 0.5% (vol/vol) Tween 80–
saline or 20 mM farnesol i.p. Kidneys from mice with i.p.
farnesol had 2  104 CFU/g by 12 h, whereas those from
mice without farnesol required 48 h to reach this level (Fig. 8).
By this time the entire kidney was fully colonized by C. albi-
cans, both grossly and by histopathology. Farnesol i.p. did not
alter C. albicans morphology in kidneys. Extensive filamenta-
tion was observed for all organs examined, i.e., kidney, liver,
spleen, and brain. Finally, we note the congruence in timing for
the disappearance of fluorescent farnesol from the serum by
12 h, coinciding with the more-rapid kidney colonization (Fig.
8), and more rapid onset of lethality (Fig. 5).
FIG. 5. Effect of orally administered mixed isomers of farnesol on
mouse mortality caused by intravenous administration of wild-type C.
albicans A72. E, LD50 (1.3  10
6) of C. albicans-only control; x, LD50
of C. albicans with farnesol in drinking water; each group contained
seven replicates. Farnesol oral and i.v. control groups showed 100%
survival.
FIG. 6. Effect of i.p. administered E,E-farnesol on mouse mortality
caused by intravenous administration of wild-type C. albicans A72.
Each group of treatments had 40 replicates. All control groups con-
tained five replicates. E, C. albicans LD50 (1.3  10
6) dose, i.v. only; F,
C. albicans LD50 and 1 ml of i.p. 20 mM farnesol. Farnesol i.p. control
and the 0.5% Tween 80 i.p. control never showed mortality.
FIG. 7. Effect of i.p. administered E,E-farnesol on mouse mortality
caused by sublethal levels of wild-type C. albicans A72. Each group
contained 15 replicates. E, sublethal C. albicans given i.v. with a single
i.p. injection (1 ml) of 0.5% Tween 80 in sterile saline; F, sublethal C.
albicans with a single i.p. injection (1 ml) of 20 mM farnesol. The
farnesol i.p. and 0.5% Tween 80 i.p. controls (with no C. albicans)
showed no mortality.
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DISCUSSION
This work demonstrates that farnesol, both endogenous and
exogenous, accelerates the mortality of candidemia. Past stud-
ies have shown that C. albicans produces farnesol in vitro (12)
and that increased production of farnesol in vivo is accompa-
nied by increased virulence of C. albicans (27). In this regard,
we previously showed that C. albicans cells pretreated with 0.5
to 1.0 M fluconazole produced 6 to 12 times more farnesol
(14) and were 4.2 to 8.5 times more lethal (27) than untreated
cells. To substantiate this observation on the importance of
farnesol, we sought an alternate method for studying the
pathogenicity of C. albicans cells differing in their farnesol
excretion levels. This method employed a knockout mutant
defective in the phosphatase which converts farnesyl diphos-
phate to farnesol (11, 49, 50). Two such genes have been
identified for Saccharomyces cerevisiae, DPP1 (50) and LPP1
(49). Their homologs in C. albicans are DPP3 and DPP2, re-
spectively (Candida DB database). We chose to knock out
DPP3, because in S. cerevisiae (11) the rates for dephosphor-
ylation of farnesyl diphosphate catalyzed by particulate frac-
tions from the lpp1, dpp1, and double-knockout lpp1
dpp1 strains were 85, 25, and 8%, respectively (11).
We used the gene deletion system developed by Noble and
Johnson (31). This system has the essential feature that the
multiply auxotrophic parent (SN152) is still pathogenic for
mice (31), and its LD50 is close to that of strain A72 (27). We
have now shown the following: (i) a double-knockout strain
with a mutated DPP3 gene, which encodes a farnesyl-PP phos-
phatase (11), produced 6 times less farnesol and was ca. 4.2
times less pathogenic than its SN152 parent; (ii) when DPP3
was reconstituted, both farnesol production and pathogenicity
were regained; (iii) farnesol is harmless by itself; (iv) mice
challenged with C. albicans in the presence of i.p. farnesol died
earlier and had a lower percent survival (P  0.03) than did
control mice receiving C. albicans with an i.p. injection of
Tween 80; and (v) the more-rapid onset of mortality among
mice administered farnesol concurrently with C. albicans cor-
related with a more-rapid kidney colonization as measured by
higher numbers of CFU of C. albicans on kidneys. For these
reasons we suggest that farnesol fits the definition of a viru-
lence factor (7) and that it be added to the list of virulence
factors for C. albicans (9, 28, 33). Although we prefer the idea
that DPP3 exerts its effect on pathogenicity through a change
in farnesol levels, we cannot rule out other cell activities that
may require the Dpp3 isoprenoid phosphate phosphatase.
C. albicans is a diploid organism. In the progression from
SN152 to KWN1 and KWN2, we knocked out one copy of
DPP3 and then the other, while for KWN3 and KWN4, we
restored one copy and then another. For C. albicans SC5314,
the two copies of the DPP3 structural gene have identical
sequences. Yet the farnesol production levels (Table 2) for
these mutants suggest that the gene removed in making KWN1
was active whereas that removed in making KWN2 was not
and, by extension, KWN3 and -4 were both reconstituted with
active genes. The likelihood of this scenario is supported by the
high frequency of haploinsufficiency mutants found by Uhl et
al. (51) in a transposon mutagenesis study. For these mutants,
knocking out a single copy of the gene is sufficient to generate
the observed phenotype (51). Our farnesol production data
(Table 2) suggest that DPP3 fits this category.
Our evidence suggests that farnesol, as produced by A72 and
most other strains of C. albicans (14), contributes to fungal
pathogenicity. In contrast, farnesoic acid, as produced by strain
10231 (35), does not. In our parallel tests, the LD50 dose for
A72 (27) was ca. 10-fold lower than that for 10231 (Table 2).
Perhaps some of the C. albicans strains found by others to be
naturally attenuated in mouse virulence (33) are also deficient
in farnesol production. This difference in effectiveness between
farnesol and farnesoic acid may be because farnesol is li-
pophilic and able to cross membranes, whereas farnesoic acid
is ionic. Indeed, animals such as rats and mice remove farnesol
by converting it to farnesoic acid and a highly soluble farnesol-
derived dicarboxylic acid prior to excretion in the urine (3).
It has been established that dimorphism is strongly associ-
ated with fungal invasiveness and dissemination for both ani-
mal models (25, 43) and, via histopathology, human patients
(6). With regard to farnesol’s mode of action as a virulence
factor, no firm conclusions can be made yet. However, five
ideas seem pertinent. First, farnesol is an autoregulator of
Candida dimorphism in vitro (12). There is, of course, no
assurance that the in vitro mode of action preventing germ
tube formation and the in vivo mode of action are related.
Indeed, the predominant cell types in infected kidneys are
filamentous, i.e., pseudohyphae and hyphae. Second, farnesol
could promote invasiveness by altering the membrane fluidity
of host cells. The lipophilic properties of free farnesol would
favor its membrane localization. For instance, Cole et al. (10)
describe the likely intercellular transmigration (termed per-
sorption) whereby yeast cells of C. albicans cross the mucosal
barrier into the bloodstream. As another case in point, Saidi et
al. (40) found that gingival fibroblasts lost viability when
treated with 10 M farnesol. Third, if farnesol contributes to
the lysis of even a few red blood cells, the iron made available
could enhance pathogenicity. Animals often sequester iron in
an attempt to starve iron-requiring pathogens (52), and thus,
FIG. 8. Time course of kidney infection by C. albicans A72 with or
without i.p. farnesol. E, C. albicans, 1.3  106 cells, i.v. only; F, C.
albicans, i.v., with 1 ml of 20 mM farnesol i.p. Each value is the average
for three kidneys from three mice. Undiluted kidney homogenate (100
l) was plated onto BiGGY agar plates (30). Values of 20,000 CFU/g
of kidney correspond to actual plate counts of 800 CFU, deemed too
numerous to count.
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red blood cell lysis would make critical iron supplies available
to those pathogens. C. albicans does not produce an iron-
binding siderophore (15), but it can use hemin as an iron
source (15). The bacterium Staphylococcus aureus uses hemo-
lysin to punch holes in host red blood cells and then acquires
iron from the hemoglobin released (46). Perhaps C. albicans
uses farnesol to punch holes in host red blood cells for similar
reasons. Fourth, farnesol could protect C. albicans cells from
destruction following ingestion by professional phagocytes by
countering their oxidative burst. Westwater et al. (53) showed
that in vitro farnesol protected yeast cells from oxidative stress
from both hydrogen peroxide and superoxide anion-generating
agents. Fifth, farnesol could interfere with aspects of host de-
fense necessary for the animals to survive pathogenesis. It is
known that C. albicans infections delay induction of proinflam-
matory cytokines, thus giving C. albicans an advantage during
invasion compared with other fungi. For instance, the survival
of Candida glabrata-infected mice was associated with rapid
induction of three proinflammatory cytokines, tumor necrosis
factor alpha, interleukin-12, and interferon gamma (4), and of
equal importance, the lack of induction for the anti-inflamma-
tory cytokine interleukin-10 (4). Thus, farnesol could interfere
with the induction of appropriate cytokines by the host. Finally,
these possible mechanisms are not mutually exclusive; farnesol
could have multiple modes of action during pathogenesis
which are operative at different times.
In summary, we have identified the first gene, DPP3, having
a role in farnesol production by C. albicans, made a knockout
mutant of that gene, and shown that the gene product farnesol
acts as a virulence factor as well as a quorum-sensing molecule
(29). Thus, if there is any antifungal therapeutic potential for
farnesol (35) or its analogs (45), they would likely be restricted
to topical applications.
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sis, Joachim Morschhäuser for the plasmid containing the SAT1 flipper
cassette, and Patrick Dussault and Roman Shchepin for synthesizing
the fluorescent farnesol.
This work was supported by grants from the National Science Foun-
dation (grant number MCB-0110999), the University of Nebraska To-
bacco Settlement Biomedical Research Enhancement Fund, the John
C. and Nettie V. David Memorial Trust Fund, and the Farnesol and
Candida albicans Research Fund, University of Nebraska Foundation.
REFERENCES
1. Barrett-Bee, K., Y. Hayes, R. G. Wilson, and J. F. Ryley. 1985. A comparision
of phospholipase activity, cellular adherence and pathogenicity of yeasts.
J. Gen. Microbiol. 131:1217–1221.
2. Binet, L., P. Binet, M. Miocque, H. Morin, C. Pechery, and M. Roux. 1972.
Le Farnésol, substance psycho-sédative et spasmolytique. Thérapie 27:893–
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